Greg McDermott1, Xiaoqing Fu2,3, John H Stone1,4, Rachel Wallwork1,4, Yuqing Zhang1,2,4,3, Hyon K Choi1,2,4,3, Zachary S Wallace1,2,4,3. 1. Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston. 2. Clinical Epidemiology Program, Massachusetts General Hospital and Harvard Medical School, Boston. 3. Mongan Institute; all at Massachusetts General Hospital and Harvard Medical School, Boston. 4. Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston.
Abstract
Importance: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic small vessel vasculitis characterized by circulating ANCAs targeting proteinase 3 (PR3) or myeloperoxidase (MPO) and associated with excess morbidity and mortality. Myeloperoxidase-ANCA-positive AAV and PR3-ANCA-positive AAV are increasingly recognized to have differences in genetic risk, pathogenesis, and response to treatment. Risk factors for AAV, including cigarette smoking, are poorly understood. Objective: To examine the association between cigarette smoking and AAV. Design, Setting, and Participants: This case-control study included a consecutive inception cohort of 484 patients with AAV diagnosed from 2002 to 2017 compared with a cohort of sex-, race-, and age-matched controls. Eleven cases were excluded owing to discordant smoking information in the electronic health record. Controls were randomly selected from participants recruited to the Partners HealthCare Biobank between its inception in 2010 and 2018 and who completed a smoking questionnaire and were not diagnosed with AAV (n = 30 536). Exposures: Smoking status (current, former, never) and pack-years of cigarette smoking were determined from review of the electronic medical record and smoking questionnaires. Main Outcomes and Measures: Patients with AAV were individually matched with 3 randomly-selected controls based on sex, race, and age (within 2 years difference). Conditional logistic regression was performed to examine the association between cigarette smoking and AAV using odds ratios (OR) and 95% confidence intervals (CIs). Results: Overall, 473 cases were matched with 1419 controls (mean [SD] age, 59 [16] years; 281 women [59%], 396 white [84%]). Patients with AAV were more likely to be former (OR, 1.6; 95% CI, 1.3-2.0) or current smokers (OR, 2.7; 95% CI, 1.8-4.1); there was a dose-response relationship according to pack-years of exposure (P < .001). These associations were especially strong among participants with MPO-ANCA-positive disease (former smokers: OR, 1.7; 95% CI, 1.3-2.3; current smokers: OR, 3.5; 95% CI, 2.1-6.1) but not in participants with PR3-ANCA-positive AAV (former smokers: OR, 1.3; 95% CI, 0.9-2.0; current smokers: OR, 1.7; 95% CI, 0.8-3.5). After stratifying by selected demographics and disease manifestations, these associations remained strong. Conclusions and Relevance: Cigarette smoking was associated with AAV, especially MPO-ANCA-positive AAV. Further studies are needed to investigate a potential pathogenic mechanism.
Importance: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic small vessel vasculitis characterized by circulating ANCAs targeting proteinase 3 (PR3) or myeloperoxidase (MPO) and associated with excess morbidity and mortality. Myeloperoxidase-ANCA-positive AAV and PR3-ANCA-positive AAV are increasingly recognized to have differences in genetic risk, pathogenesis, and response to treatment. Risk factors for AAV, including cigarette smoking, are poorly understood. Objective: To examine the association between cigarette smoking and AAV. Design, Setting, and Participants: This case-control study included a consecutive inception cohort of 484 patients with AAV diagnosed from 2002 to 2017 compared with a cohort of sex-, race-, and age-matched controls. Eleven cases were excluded owing to discordant smoking information in the electronic health record. Controls were randomly selected from participants recruited to the Partners HealthCare Biobank between its inception in 2010 and 2018 and who completed a smoking questionnaire and were not diagnosed with AAV (n = 30 536). Exposures: Smoking status (current, former, never) and pack-years of cigarette smoking were determined from review of the electronic medical record and smoking questionnaires. Main Outcomes and Measures: Patients with AAV were individually matched with 3 randomly-selected controls based on sex, race, and age (within 2 years difference). Conditional logistic regression was performed to examine the association between cigarette smoking and AAV using odds ratios (OR) and 95% confidence intervals (CIs). Results: Overall, 473 cases were matched with 1419 controls (mean [SD] age, 59 [16] years; 281 women [59%], 396 white [84%]). Patients with AAV were more likely to be former (OR, 1.6; 95% CI, 1.3-2.0) or current smokers (OR, 2.7; 95% CI, 1.8-4.1); there was a dose-response relationship according to pack-years of exposure (P < .001). These associations were especially strong among participants with MPO-ANCA-positive disease (former smokers: OR, 1.7; 95% CI, 1.3-2.3; current smokers: OR, 3.5; 95% CI, 2.1-6.1) but not in participants with PR3-ANCA-positive AAV (former smokers: OR, 1.3; 95% CI, 0.9-2.0; current smokers: OR, 1.7; 95% CI, 0.8-3.5). After stratifying by selected demographics and disease manifestations, these associations remained strong. Conclusions and Relevance: Cigarette smoking was associated with AAV, especially MPO-ANCA-positive AAV. Further studies are needed to investigate a potential pathogenic mechanism.
Authors: D J Higman; A M Strachan; L Buttery; R C Hicks; D R Springall; R M Greenhalgh; J T Powell Journal: Arterioscler Thromb Vasc Biol Date: 1996-04 Impact factor: 8.311
Authors: Susan L Hogan; Karen K Satterly; Mary Anne Dooley; Patrick H Nachman; J Charles Jennette; Ronald J Falk Journal: J Am Soc Nephrol Date: 2001-01 Impact factor: 10.121
Authors: Daniela Pelclová; Jirina Bartůnková; Zdenka Fenclová; Jindriska Lebedová; Marie Hladíková; Hana Benáková Journal: Arch Environ Health Date: 2003-10
Authors: C Mukhtyar; R Lee; D Brown; D Carruthers; B Dasgupta; S Dubey; O Flossmann; C Hall; J Hollywood; D Jayne; R Jones; P Lanyon; A Muir; D Scott; L Young; R A Luqmani Journal: Ann Rheum Dis Date: 2008-12-03 Impact factor: 19.103
Authors: Matteo Goldoni; Silvia Bonini; Maria L Urban; Alessandra Palmisano; Giuseppe De Palma; Elisa Galletti; Marco Coggiola; Carlo Buzio; Antonio Mutti; Augusto Vaglio Journal: Ann Intern Med Date: 2014-08-05 Impact factor: 25.391
Authors: Paul A Lyons; Tim F Rayner; Sapna Trivedi; Julia U Holle; Richard A Watts; David R W Jayne; Bo Baslund; Paul Brenchley; Annette Bruchfeld; Afzal N Chaudhry; Jan Willem Cohen Tervaert; Panos Deloukas; Conleth Feighery; Wolfgang L Gross; Loic Guillevin; Iva Gunnarsson; Lorraine Harper; Zdenka Hrušková; Mark A Little; Davide Martorana; Thomas Neumann; Sophie Ohlsson; Sandosh Padmanabhan; Charles D Pusey; Alan D Salama; Jan-Stephan F Sanders; Caroline O Savage; Mårten Segelmark; Coen A Stegeman; Vladimir Tesař; Augusto Vaglio; Stefan Wieczorek; Benjamin Wilde; Jochen Zwerina; Andrew J Rees; David G Clayton; Kenneth G C Smith Journal: N Engl J Med Date: 2012-07-19 Impact factor: 91.245
Authors: Kathleen Chang; So Min Yang; Seong Heon Kim; Kyoung Hee Han; Se Jin Park; Jae Il Shin Journal: Int J Mol Sci Date: 2014-12-03 Impact factor: 5.923